Lite Strategy, Inc.

What they do

Lite Strategy was a pharmaceutical company developing cancer therapies, including voruciclib (CDK9 inhibitor) and zandelisib (PI3K inhibitor). After a strategic alternatives review, the company discontinued clinical development of voruciclib in 2024 and, in August 2025, implemented a Litecoin Treasury Strategy funded by a $100 million PIPE. The company now describes itself as the first U.S. public company to adopt Litecoin as its primary treasury reserve asset and manages that treasury through sales, covered calls and share repurchases.

Revenue drivers

• Litecoin treasury operations — The company generates cash by selling portions of its LTC holdings and by writing covered call options on LTC. Proceeds have been used to fund share repurchases; this is the active capital allocation engine described in the July 2026 earnings release.
• Pharmaceutical pipeline (minimal/legacy) — The company retains pre-clinical drug candidates voruciclib and zandelisib. Clinical development of voruciclib was discontinued in 2024, and the 10-K indicates no product revenue is currently generated.
• Reported revenue — Annual revenue was $65.3M in 2024 but $0.00 in 2025, and all four most recent quarters (through 2025-06-30) show $0.00 revenue. The company has no ongoing commercial product sales.

Recent performance

Reported annual revenue fell from $65.3M in 2024 to $0.00 in 2025, and the most recent quarterly revenue figures are all $0.00. Annual net income swung from $17.8M in 2024 to a net loss of $15.9M in 2025, with operating cash flow of negative $20.8M in 2025. As of March 31, 2026, total assets were $57.8M, liabilities were $952,000, shareholder equity was $56.8M, and cash and equivalents were $7.5M. In a July 30, 2026 earnings release, the company said it repurchased approximately 4.9 million shares (13% of shares outstanding) since December 2025 at an average price of $1.11, deploying about $5.4 million funded through treasury operations. The same release stated that as of July 17, 2026, Lite Strategy held 819,070 LTC against 31,882,648 shares outstanding, with cash of $5.7 million and total liabilities of $1.1 million at fiscal year-end 2026 (preliminary, unaudited).

Strategy

Management's stated strategy is active Litecoin treasury management, including selling measured portions of the LTC holdings and writing covered calls to fund share repurchases when the stock trades below net asset value (NAV). The company intends to continue the repurchase program as long as it is value accretive and to fund buybacks only through treasury operations, preserving a debt-free balance sheet. It also says it is pursuing additional ways to grow Litecoin backing per share and to build out the broader Litecoin ecosystem. The 10-K mentions the possibility of commencing Litecoin mining activities and continued assessment of its pre-clinical drug pipeline. The company is managed by CEO and CFO Jay File, with GSR's Joshua Riezman as a Board member and Chief Strategy Officer of GSR.

Risks

• Litecoin price exposure — The company's primary asset is Litecoin, so a decline in LTC price would directly reduce the value of its treasury and its reported net asset value.
• No operating revenue — Reported revenue was $0.00 in 2025 and each of the last four quarters, so cash generation depends on treasury sales and covered call premiums rather than a commercial business.
• Historical pharmaceutical wind-down — Clinical development of voruciclib was discontinued in 2024 and the remaining pipeline consists of pre-clinical candidates, leaving no near-term drug revenue.
• Digital asset accounting and custody — The company accounts for digital assets, related receivables, covered call options and warrants under specific fair-value policies, and the 10-K flags risks in safekeeping cryptocurrency assets.

Outlook

Management says it intends to continue the share repurchase program for as long as it remains value accretive to stockholders, funding buybacks through active treasury management only. It plans to preserve low operating cash burn and a debt-free balance sheet while seeking additional ways to grow Litecoin backing per share and build out the Litecoin ecosystem. The company also states it may commence Litecoin mining activities and anticipates further investigational research and development on its drug candidate pipeline in the coming months. The July 2026 earnings release cautions that fiscal year 2026 financial information is preliminary and unaudited.